- NEWS AND VIEWS
Vaccine boosts T cells that target pancreatic tumours
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 618, 37-38 (2023)
doi: https://doi.org/10.1038/d41586-023-01526-8
References
Rojas, L. A. et al. Nature 618, 144–150 (2023).
Balachandran, V. P. et al. Nature 551, 512–516 (2017).
Łuksza, M. et al. Nature 606, 389–395 (2022).
Park, W., Chawla, A. & O’Reilly, E. M. JAMA 326, 851–862 (2021).
Ott, P. A. et al. Cell 183, 347–362 (2020).
Sahin, U. et al. Nature 547, 222–226 (2017).
Kreiter, S. et al. Nature 520, 692–696 (2015).
Alspach, E. et al. Nature 574, 696–701 (2019).
Abelin, J. G. et al. Immunity 51, 766–779 (2019).
Racle, J. et al. Nature Biotechnol. 37, 1283–1286 (2019).
Racle, J. et al. Immunity https://doi.org/10.1016/j.immuni.2023.03.009 (2023).
Huff, A. L., Jaffee, E. M. & Zaidi, N. J. Clin. Invest. 132, e156211 (2022).
Competing Interests
A.L.H. is co-founder and a paid consultant for Adventris Pharmaceuticals, Inc. N.Z. receives research support from Bristol Myers Squibb, has served on an advisory board for Genentech, and receives other support from Adventris Pharmaceuticals.